ArticleAnatolian journal of cardiology2025
Protective Effect of Amifostine on Radiotherapy-Applied Cardiovascular Tissue.
Article in Anatolian journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mechanistic insights into the mitigating role of dapagliflozin against radiation-triggered myocardial apoptosis: gating to AMPK-regulated autophagic machinery.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Reply to Letter to the Editor: "Comment On: Protective Effect of Amifostine on Radiotherapy Applied Cardiovascular Tissue".Anatolian journal of cardiology · 2025Article
- Comment On: Protective Effect of Amifostine on Radiotherapy Applied Cardiovascular Tissue.Anatolian journal of cardiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe present study evaluates the protective effect of amifostine (AMI) on acute toxicity in large vessels and the heart in rats with radiotherapy (RT) applied to the thorax.
methodsTwenty-one Wistar albino rats were randomly assigned to 3 groups: Alone RT (n = 7), amifostine plus RT (AMI+RT, n = 7), and control (n = 7) groups. The rats in the RT and AMI+RT groups received a single dose of 20 Gy radiation to the entire thorax. Prior to irradiation, AMI was administered intraperitoneally at a dose of 200 mg/kg, 30 minutes before the procedure. Five days after irradiation, the levels of p53, CD68, and COX in the vascular tissue (aorta) were measured, along with the levels of malondialdehyde (MDA) and glutathione (GSH) in the aortic and heart tissues.
resultsThe results showed that the level of MDA significantly increased after irradiation, but GSH levels did not change (P < .001 and P = 0.138). Malondialdehyde levels were significantly reduced by AMI, and GSH levels increased (P = .031 and P = .007). When comparing the control group with AMI + RT, MDA and glutathione levels were similar (P = .314 and P = .136). Histopathological evaluation revealed increased cellular inflammation (P = .002) and vascular damage (P = .015) in aortic tissue after thoracic RT irradiation, but no difference in terms of myofibrosis (P = .901) in heart tissue.
conclusionAMI has a radioprotective and antioxidant effect against RT-induced cardiovascular toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.